 "Cipla gains on Q4 results")
Shares of Mumbai-based drug maker Cipla are trading higher by 3% to Rs 667 on the BSE after the total income posted by the company surged from Rs 10,439 crore to Rs 11,511 crore on year-on-year basis. The domestic sales in the Jan-March quarter in the current fiscal appreciated from Rs 900 crore in the year ago period to Rs 1,086 crore depicting a jump of 21% on the back of increased sales in respiratory, anti-infective, cardiac and gastro-intestinal categories.
Meanwhile, exports of formulations rose 30% to Rs 1,690 crore during the March quarter in the current year.
However, the company reported consolidated net profit of Rs 260 crore for the March quarter as against Rs261 crore for the corresponding period previous year.
The stock opened at Rs 645 and touched a high of Rs 673 on the BSE. At 11.45 AM, A total of 156,430 shares changed hands on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%